View Older Stories View More Recent Stories

Jul 17, 2025 10:29AM Johnson & Johnson (JNJ) PT Raised to $185 at RBC Capital
Jul 17, 2025 09:32AM Johnson & Johnson (JNJ) PT Raised to $190 at UBS
Jul 17, 2025 08:01AM Johnson & Johnson gets FDA priority review for bladder cancer treatment
Jul 17, 2025 07:22AM Johnson & Johnson (JNJ) PT Raised to $167 at Guggenheim
Jul 17, 2025 06:07AM Johnson & Johnson (JNJ) PT Raised to $185 at Goldman Sachs
Jul 16, 2025 03:19PM Johnson & Johnson (JNJ) PT Raised to $165 at Stifel
Jul 16, 2025 06:21AM Johnson & Johnson (JNJ) Tops Q2 EPS by 9c, Beats on Revenue; Offers Strong FY25 Guidance
Jul 16, 2025 06:21AM Stocks expected to have increasing option volume: MS GS BAC JNJ PNC PGR
Jul 16, 2025 02:00AM Johnson & Johnson earnings preview Q2: flat print expected, tariff impact in focus
Jul 15, 2025 11:20AM Johnson & Johnson (JNJ) call put ratio 1.7 calls to 1 put into quarter results
Jul 15, 2025 06:30AM Johnson & Johnson (JNJ) call put ratio 1.2 calls to 1 put into quarter results
Jul 10, 2025 06:15AM Wolfe Research Reiterates Outperform Rating on Johnson & Johnson (JNJ)
Jul 10, 2025 06:02AM Goldman Sachs Reiterates Conviction Buy Rating on Johnson & Johnson (JNJ)
Jul 8, 2025 08:03AM Johnson & Johnson submits FDA application for CAPLYTA schizophrenia use
Jun 23, 2025 07:32AM Johnson & Johnson (JNJ) reports IMAAVY showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis
Jun 20, 2025 08:17AM Johnson & Johnson (JNJ) says IMBRUVICA received positive CHMP opinion for the treatment of patients with previously untreated MCL
Jun 13, 2025 11:00AM Johnson & Johnson (JNJ) says dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Jun 12, 2025 04:10PM Kenvue (KVUE) considers selling skin health and beauty brands, sources say - Reuters
Jun 12, 2025 11:00AM Johnson & Johnson (JNJ) says bleximenib demonstrated promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Jun 11, 2025 08:05AM Johnson & Johnson (JNJ) Reports New guselkumab showing its significantly inhibits progression of joint structural damage in active psoriatic arthritis
Jun 10, 2025 04:52PM Johnson & Johnson (JNJ) Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
Jun 3, 2025 10:47AM Johnson & Johnson's (JNJ) DARZALEX FASPRO shows strong data
Jun 3, 2025 10:46AM Johnson & Johnson (JNJ): Single infusion of CARVYKTI delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
Jun 3, 2025 10:46AM Johnson & Johnson (JNJ) announces promising early results from TsAb
May 20, 2025 07:30PM Johnson & Johnson (JNJ) FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO
May 20, 2025 11:04AM FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
May 13, 2025 03:01PM Johnson & Johnson (JNJ) call put ratio 1 call to 1 put as share price down 3.1%
May 13, 2025 08:55AM Leerink Partners Downgrades Johnson & Johnson (JNJ) to Market Perform
May 9, 2025 08:05AM Johnson & Johnson (JNJ) reports Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
May 7, 2025 05:27AM Johnson & Johnson (JNJ) call put ratio 1 call to 1.5 puts
May 5, 2025 08:06AM Johnson & Johnson (JNJ) says TREMFYA positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
May 5, 2025 08:05AM Johnson & Johnson (JNJ) says TREMFYA delivered sustained clinical and endoscopic remission in ulcerative colitis through two years
May 1, 2025 05:24AM Goldman Updating US May Directors' Cut Conviction List Names
Apr 30, 2025 08:29AM Johnson & Johnson (JNJ) receives FDA approval for IMAAVY
Apr 28, 2025 11:34AM HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
Apr 26, 2025 04:00AM Medtech Q1 earnings preview: Potential tariff exposure
Apr 21, 2025 09:39AM Johnson & Johnson (JNJ) unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
Apr 16, 2025 11:08AM TD Cowen: 'Johnson & Johnson (JNJ) Is Prepared to Absorb Tariff Costs'
Apr 16, 2025 09:58AM UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
Apr 15, 2025 06:41AM Johnson & Johnson (JNJ) Tops Q1 EPS by 19c; adjusts forecast
Apr 15, 2025 06:28AM Johnson & Johnson (JNJ) Raises Quarterly Dividend 4.8% to $1.30; 3.4% Yield
Apr 15, 2025 04:00AM Analysts brace for volatile Johnson & Johnson Q1 amid Part D impact, legal setbacks
Apr 14, 2025 10:28AM Johnson & Johnson (JNJ) call put ratio 1 call to 1.4 puts into quarter results
Apr 14, 2025 06:10AM Johnson & Johnson (JNJ) call put ratio 1 call to 1.3 puts into quarter results
Apr 9, 2025 09:19AM Pharma stocks slide after Trump signals tariffs on sector
Apr 8, 2025 06:16AM Johnson & Johnson (JNJ) highlights new data that showcase the strength of nipocalimab
Apr 8, 2025 05:07AM Goldman Sachs Upgrades Johnson & Johnson (JNJ) to Buy
Apr 4, 2025 10:47AM UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
Apr 4, 2025 08:05AM Johnson & Johnson (JNJ) announces TREMFYA significantly reduced both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
Apr 3, 2025 09:21AM RBC Capital Assesses U.S. Tariff Impact Across Industries
View More Recent Stories View Older Stories